(Q36723151)

15 August 2017

1 reference

title

Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy (English)

1 reference

15 August 2017

1 reference

1

Fred Saad

1 reference

15 August 2017

2

Cora N Sternberg

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

15 August 2017

published in

Nature Reviews Urology

1 reference

15 August 2017

volume

4 Suppl 1

1 reference

15 August 2017

page(s)

S3-13

1 reference

A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

Gene expression profiling in seminoma and nonseminoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Risk of fracture after androgen deprivation for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Bisphosphonates: clinical experience

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

The medical management of prostate cancer: a multidisciplinary team approach.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

EAU guidelines on prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Natural history and treatment of bone complications in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Androgen deprivation therapy: monitoring and managing the complications

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Androgen deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

CASE 2. Osteonecrosis of the Jaws Associated With Bisphosphonate Therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0727

7 January 2021

Identifiers

DOI

10.1038/NCPURO0727

1 reference

15 August 2017

1 reference